Modern 3D Imaging Analysis and Hip Osteoarthritis
Overview:
Osteoarthritis is the commonest type of joint disorder and affects many people throughout the world. People with osteoarthritis can experience joint pain, stiffness and difficulty performing their usual daily activities. After the knee joint, the hip is the second most commonly affected joint. However, there is a lack of research into hip joint osteoarthritis, with many clinical trials focussing on the knee joint.
The Leeds Osteoarthritis Hip Cohort (LOHC) study involves assessing patients with hip osteoarthritis over 2 years. Symptoms of hip arthritis will be measured along with MRI scans and assessment of walking patterns (gait analysis). New ‘3D’ MRI analysis will be used in the study to give more detailed insight into how hip osteoarthritis progresses over time.
Clinically, radiographic changes are used to assess the progression of osteoarthritis. However, x-rays can only pick up these changes after relatively long periods of time. 3D shape modelling through the LOHC study will help to elucidate the pattern of osteoarthritis structural changes that cannot be readily appreciated on 2D imaging. This may allow more sensitive MRI biomarkers for osteoarthritis progression to be found which could be used to better assess the efficacy of treatment options.
Aims and Objectives:
The Leeds Osteoarthritis Hip Cohort (LOHC) study aims to give detailed information of how hip osteoarthritis progresses anatomically over time. MRI results will also be linked to patient symptoms to develop an understanding between the physical shape of the hip joint and symptoms that occur such as pain and stiffness. Walking tests (gait analysis) will also be performed to review if specific patterns in locomotion result from hip osteoarthritis. Better appreciation of the structural changes that occur over time as hip osteoarthritis progresses should allow better assessment of potential treatments.
Outputs
- Khokhar K, Conaghan PG. Bone in osteoarthritis: imaging and interventions. Curr Opin Rheumatol. 2022 Jan 1;34(1):73-78. 10.1097/BOR.0000000000000849. PMID: 34690277.